However, in the phase 3 trial of atezolizumab plus bevacizumab (IMbrave 150), only 15% of the patients were Barcelona Clinic Liver Cancer (BCLC) stage B, and there are no established biomarkers to make a therapeutic strategy for u-HCC except ramucirumab (AFP ≥ 400 ng/mL). This evidence concerns the gene AFP and hepatocellular carcinoma.